isoniazid + HUEXC030

**Isoniazid + HUEXC030** is a combination therapy in which isoniazid, a first-line antituberculosis antibiotic, is formulated with HUEXC030 as an excipient. This combination is investigated primarily for the treatment of pulmonary tuberculosis and to reduce the incidence and severity of anti-tuberculosis drug-induced liver injury (ATDH). Isoniazid acts as a prodrug that is activated by the mycobacterial enzyme KatG, leading to inhibition of the synthesis of mycolic acids, essential components of the mycobacterial cell wall. HUEXC030 acts as an inhibitor of amidohydrolases and cytochrome P450 family 2 subfamily E member 1 (CYP2E1), and is investigated for its hepatoprotective activity, aiming to reduce isoniazid (and other anti-tuberculosis drugs)-induced hepatic injury by modulating these enzymatic pathways. Clinical trials have included this combination as a strategy to mitigate hepatotoxicity in high-risk tuberculosis patients by genotype[2][3][4][6].

Other names

isoniazid formulated with HUEXC030